Swiss regulator gives green light to first drug to prevent Covid-19
The drug is currently only approved for use to prevent Covid-19 among people who don't receive enough protection from vaccines.
Copyright 2020 The Associated Press. All Rights Reserved
Swissmedic has issued a temporary marketing authorisation for AstraZeneca’s drug Evusheld, making it the first Covid-19 prophylaxis drug approved by the Swiss medical regulator.
This content was published on
2 minutes
Keystone-SDA/jdp
Русский
ru
Швейцарский регулятор одобрил препарат для профилактики Covid-19
This authorisation means that the drug, which is administered as an injection, can now be reimbursed by the federal government or health insurance under certain conditions. Evusheld, which is an antibody combination of Tixagevimab and Cilgavimab, is intended for people 12 years and older who aren’t able to build up sufficient immune defenses against Covid-19 from vaccines.
The federal government has already signed contracts with AstraZeneca’s Swiss subsidiary to procure the Covid-19 drug starting with 5,000 doses, according to Keystone-SDA.
Evusheld is authorised for use for Covid-19 prevention in the United States (emergency use), Japan, the European Union and several other countries.
In the UK, where AstraZeneca has its headquarters, officials recently saidExternal link they will not purchase the drug citing “insufficient data” on the duration of protection it provides against the dominant variant Omicron and its subvariants.
On Friday, the EU extended its recommendation for the drug so that it can also be used as a treatment. Swissmedic is still reviewing Evusheld for use as a treatment. However, Swiss Covid regulations allow for the drug to be used to treat Covid-19 patients under certain conditions as the company’s application is being reviewed.
Other treatments
On Friday, the World Health Organization rescinded recommendations for two Covid-19 antibody therapies, stating that new variants have rendered them obsolete.
The two therapies, sotrovimab and casirivimab-imdevimab, were designed to work by binding to the spike protein of SARS-CoV-2 to neutralise the virus’ ability to infect cells.
GSK and partner Vir Biotechnology’s sotrovimab was pulled off the US market by the Food and Drug Administration (FDA) in April.
In January, the FDA also revised its stance on Casirivimab-imdevimab, which is sold under the name REGEN-COV. It limited the use of the drug sold by Swiss firm Roche and US firm Regeneron to a smaller group of patients, citing that it is less effective against the Omicron variant.
Have you heard something about Swiss diplomacy that you’d like us to fact check?
Not all information circulating about Switzerland’s foreign relations is accurate or well understood. Tell us what you'd like us to fact check or clarify.
Researchers find high microbial diversity in glacial streams
This content was published on
Swiss researchers have discovered a surprising diversity of microorganisms in glacial streams around the world. However, this diversity is under threat as soon as it is discovered.
This content was published on
Fewer electric cars were sold in Switzerland in 2024 compared to the previous year. The electric mobility association Swiss eMobility says this is only a temporary dip.
This content was published on
Sunshine and fresh snow attracted winter sports fans to Swiss ski resorts over the holiday period. Many ski stations reported record figures.
New Year’s speech: President Keller-Sutter praises Swiss modesty
This content was published on
The Swiss president for 2025, Karin Keller-Sutter, has underlined the importance of compromise and modesty in Swiss politics in her New Year’s address to the nation.
Lindt wins ‘chocolate ball’ legal case against Aldi
This content was published on
Chocolate manufacturer Lindt & Sprüngli has won a legal case against the retailer Aldi Suisse for infringing the trademark rights of its Lindor chocolate balls.
Campaigners want Swiss central bank to hold bitcoin in reserves
This content was published on
Campaigners have launched a people's initiative to oblige the Swiss National Bank (SNB) to hold part of its reserves in bitcoin.
Switzerland welcomes 2025 with fireworks and ice plunges
This content was published on
Fireworks lit up the skies in Switzerland to celebrate New Year's Eve. Some people welcomed the new year by plunging into lakes in freezing temperatures.
Explainer: How ready is Switzerland for a new wave of Covid-19?
This content was published on
Covid-19 cases are on the rise again, sparking renewed talk of vaccination and a possible return to social distancing in the autumn.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.